Across TCGA pan-cancer cohorts, TBC1D3 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of TBC1D3’s most consistent transcriptional readouts.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TBC1D3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TBC1D3 is over-expressed in tumor.
KIRC are the cancer types where TBC1D3 tumor–normal differential expression is most reproducible.